Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Perspective Therapeutics, Inc. (CATX)
USD3.05
+0.00 (+0.00%)
US AMEX Healthcare Medical - Devices
Address
350 Hills Street 99354
Seattle, WA, US
Seattle, WA, US
CEO
Johan Spoor
Website
perspectivetherapeutics.com
IPO
2005-11-10
CIK 728387 ISIN US46489V3024
Also trades on
New York Stock Exchange American · CATX (USD)
New York Stock Exchange Arca · ISR (USD)
Description
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.05
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.73
Float Shares
48.00M
Free Float %
65.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.84% | +4.72% | -13.33% | -19.79% | +82.13% | +37.09% | +47.84% | -42.00% | -51.79% | -64.43% | -92.61% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
3.05
Low
7.00
+129.5%
Consensus
11.75
+285.2%
Median
12.00
+293.4%
High
16.00
+424.6%
DCF (Unlevered)
0.39
-87.1%
DCF (Levered)
0.39
-87.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
93% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 12 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
14.00
+359.0%
|
| Last Year | 5 |
12.20
+300.0%
|
| All Time | 12 |
14.33
+369.8%
|
Quality scores
Altman Z-Score
1.52
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%— Q1'26: -100.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-13.8% Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-11,393.0%
-
EBIT margin Medical - Devices: +6.2%-11,715.4%
-
ROIC Medical - Devices: +3.3%-162.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+14.6% Q1'26: +43.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.02× Q1'26: 0.31× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 11 EPS Ana. |
Dec 2027 7 Rev. Ana. 7 EPS Ana. |
Dec 2028 8 Rev. Ana. 8 EPS Ana. |
Dec 2029 7 Rev. Ana. 6 EPS Ana. |
Dec 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.22M
est: 4.57M (-7.6%)
|
4.61M
est: 4.57M (+0.9%)
|
4.77M
est: 4.84M (-1.4%)
|
4.76M
est: 5.14M (-7.4%)
|
5.92M
est: 5.87M (+1.0%)
|
7.31M
est: 7.33M (-0.2%)
|
9.68M
est: 10.10M (-4.2%)
|
10.05M
est: 10.03M (+0.2%)
|
7.10M
est: 11.14M (-36.2%)
|
10.80M
est: 11.14M (-3.1%)
|
1.43M
est: 1.40M (+2.4%)
|
—
est: 1.35M (-100.0%)
|
884.0K
est: 1.06M (-16.5%)
|
583.0K
485.8K – 680.2K
-44.9% YoY
|
547.6K
502.0K – 593.2K
-6.1% YoY
|
17.31M
15.87M – 18.75M
+3,060.7% YoY
|
249.58M
228.78M – 270.37M
+1,342.0% YoY
|
348.48M
319.44M – 377.52M
+39.6% YoY
|
| EBITDA |
-3.89M
est: -1.85M (-110.4%)
|
-4.05M
est: -1.85M (-119.2%)
|
-4.39M
est: -1.96M (-124.3%)
|
-6.19M
est: -2.08M (-197.2%)
|
-6.70M
est: -2.38M (-181.9%)
|
-5.30M
est: -2.97M (-78.6%)
|
-3.48M
est: -4.09M (+15.1%)
|
-3.43M
est: -4.06M (+15.7%)
|
-14.84M
est: -4.51M (-228.8%)
|
-7.39M
est: -4.51M (-63.8%)
|
-39.96M
est: -751.7K (-5,215.9%)
|
10.46M
est: -725.2K (+1,542.3%)
|
-100.31M
est: -568.5K (-17,544.3%)
|
-313.0K
-365.2K – -260.9K
+44.9% YoY
|
-294.0K
-318.5K – -269.5K
+6.1% YoY
|
-9.29M
-10.07M – -8.52M
-3,060.7% YoY
|
-134.01M
-145.17M – -122.84M
-1,342.0% YoY
|
-187.11M
-202.70M – -171.52M
-39.6% YoY
|
| EBIT |
-4.59M
est: -1.87M (-145.2%)
|
—
est: -1.87M (+100.0%)
|
—
est: -1.98M (+100.0%)
|
-6.31M
est: -2.11M (-199.3%)
|
-6.73M
est: -2.40M (-179.8%)
|
-5.28M
est: -3.00M (-75.7%)
|
—
est: -4.14M (+100.0%)
|
-3.44M
est: -4.11M (+16.4%)
|
-15.18M
est: -4.57M (-232.5%)
|
—
est: -4.57M (+100.0%)
|
-40.94M
est: -758.1K (-5,300.2%)
|
-81.42M
est: -731.4K (-11,033.3%)
|
-103.56M
est: -573.4K (-17,961.5%)
|
-315.7K
-368.3K – -263.1K
+44.9% YoY
|
-296.5K
-321.3K – -271.8K
+6.1% YoY
|
-9.37M
-10.15M – -8.59M
-3,060.7% YoY
|
-135.15M
-146.42M – -123.89M
-1,342.0% YoY
|
-188.71M
-204.44M – -172.98M
-39.6% YoY
|
| Net Income |
-5.96M
est: -3.87M (-54.2%)
|
-3.68M
est: -38.66M (+90.5%)
|
-4.71M
est: -57.98M (+91.9%)
|
-6.16M
est: -57.98M (+89.4%)
|
-6.70M
est: -68.72M (+90.3%)
|
-4.85M
est: -53.69M (+91.0%)
|
-3.27M
est: -27.92M (+88.3%)
|
-3.19M
est: -17.18M (+81.4%)
|
-14.67M
est: -32.35M (+54.7%)
|
-7.15M
est: -32.35M (+77.9%)
|
-46.51M
est: -7.38M (-530.1%)
|
-79.28M
est: -63.57M (-24.7%)
|
-103.12M
est: -89.16M (-15.7%)
|
-83.85M
-101.06M – -66.64M
+6.0% YoY
|
-88.91M
-113.44M – -64.38M
-6.0% YoY
|
-79.32M
-100.69M – -57.95M
+10.8% YoY
|
-21.41M
-23.72M – -19.09M
+73.0% YoY
|
44.29M
39.49M – 49.09M
+306.9% YoY
|
| SGA |
3.72M
est: 17.60M (-78.8%)
|
3.89M
est: 17.60M (-77.9%)
|
5.14M
est: 18.64M (-72.4%)
|
6.23M
est: 19.81M (-68.6%)
|
6.83M
est: 22.61M (-69.8%)
|
6.85M
est: 28.24M (-75.7%)
|
7.55M
est: 38.93M (-80.6%)
|
7.13M
est: 38.67M (-81.6%)
|
14.21M
est: 42.94M (-66.9%)
|
9.43M
est: 42.94M (-78.0%)
|
21.06M
est: 14.77M (+42.6%)
|
26.61M
est: 14.25M (+86.7%)
|
30.23M
est: 11.17M (+170.6%)
|
6.15M
5.13M – 7.18M
-44.9% YoY
|
5.78M
5.30M – 6.26M
-6.1% YoY
|
182.65M
167.43M – 197.87M
+3,060.7% YoY
|
2.63B
2.41B – 2.85B
+1,342.0% YoY
|
3.68B
3.37B – 3.98B
+39.6% YoY
|
| EPS |
-0.14
est: -0.06 (-133.3%)
|
-0.07
est: -0.60 (+88.8%)
|
-0.09
est: -0.90 (+90.5%)
|
-0.11
est: -0.90 (+87.8%)
|
-0.12
est: -1.07 (+88.8%)
|
-0.07
est: -0.83 (+91.3%)
|
-0.05
est: -0.43 (+88.8%)
|
-0.06
est: -0.27 (+78.2%)
|
-0.27
est: -0.50 (+46.0%)
|
-0.13
est: -0.50 (+74.0%)
|
-0.85
est: -0.10 (-750.0%)
|
-1.23
est: -0.85 (-44.4%)
|
-1.40
est: -1.23 (-13.6%)
|
-1.16
-1.37 – -0.90
+5.8% YoY
|
-1.16
-1.54 – -0.87
-0.2% YoY
|
-1.09
-1.36 – -0.79
+5.9% YoY
|
-0.29
-0.32 – -0.26
+73.5% YoY
|
0.60
0.54 – 0.67
+306.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | Wedbush | Outperform | Outperform | Maintain |
| 2026-04-20 | Wedbush | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-91.61M
OE per share TTM
-1.10
Owner's Yield
-22.79%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
386.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 5.50M | 8.16% | — | — | 5.50M | — | IN | Delaware | 2024-11-07 | ↗ |
| 2 | FMR LLC | 5.50M | 8.16% | 5.50M | — | 5.50M | — | HC | Delaware | 2024-11-07 | ↗ |
| 3 | EIN #00-0000000 | 4.80M | 7.10% | — | 4.80M | — | 4.80M | IA, HC | Jersey, Channel Islands | 2024-11-14 | ↗ |
| 4 | (1) BlackRock, Inc. | 4.04M | 6.00% | 3.92M | — | 4.04M | — | HC | Delaware | 2024-11-08 | ↗ |
| 5 | Avidity Capital Partners (GP) LLC | 3.59M | 5.30% | — | 3.59M | — | 3.59M | OO | Delaware | 2024-11-14 | ↗ |
| 6 | Avidity Capital Partners Fund (GP) LP | 3.59M | 5.30% | — | 3.59M | — | 3.59M | PN, OO | Delaware | 2024-11-14 | ↗ |
| 7 | Avidity Partners Management (GP) LLC | 3.59M | 5.30% | — | 3.59M | — | 3.59M | OO | Delaware | 2024-11-14 | ↗ |
| 8 | Avidity Partners Management LP | 3.59M | 5.30% | — | 3.59M | — | 3.59M | IA, PN | Delaware | 2024-11-14 | ↗ |
| 9 | David Witzke | 3.59M | 5.30% | — | 3.59M | — | 3.59M | IN | Delaware | 2024-11-14 | ↗ |
| 10 | Michael Gregory | 3.59M | 5.30% | — | 3.59M | — | 3.59M | IN | Delaware | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 58 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X - S&P Biotech ETF CURE.AX | 0.11% | 40.6K | 0.45% |
| 2 | State Street SPDR S&P Biotech ETF XBI | 0.11% | 12.18M | 0.35% |
| 3 | iShares Micro-Cap ETF IWC | 0.07% | 1.04M | 0.60% |
| 4 | Vanguard Global Momentum Factor ETF VMO.TO | 0.06% | 217.9K | 0.38% |
| 5 | Vanguard U.S. Momentum Factor ETF VFMO | 0.03% | 547.3K | 0.13% |
| 6 | Pacer WealthShield ETF PWS | 0.02% | 5.6K | 0.60% |
| 7 | iShares Biotechnology ETF IBB | 0.02% | 1.95M | 0.44% |
| 8 | iShares Russell 2000 Value ETF IWN | 0.02% | 2.91M | 0.24% |
| 9 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.02% | 17.7K | 0.89% |
| 10 | Vanguard Russell 2000 Value ETF VTWV | 0.02% | 195.0K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
1.23M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,225,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Woods Lori A | Director | A-Award | A | Stock option (right to buy) | 50,000 | 5.35 | 267.5K | 50,000 | D | ↗ |
| 2026-03-02 | Williamson Robert F III | Director | A-Award | A | Stock option (right to buy) | 50,000 | 5.35 | 267.5K | 50,000 | D | ↗ |
| 2026-03-02 | Spoor Johan M. | Director / Officer | A-Award | A | Stock option (right to buy) | 735,000 | 5.35 | 3.93M | 735,000 | D | ↗ |
| 2026-03-02 | Puhlmann Markus | Officer | A-Award | A | Stock option (right to buy) | 150,000 | 5.35 | 802.5K | 150,000 | D | ↗ |
| 2026-03-02 | Morich Frank | Director | A-Award | A | Stock option (right to buy) | 50,000 | 5.35 | 267.5K | 50,000 | D | ↗ |
| 2026-03-02 | Martinez Maria E | Director | A-Award | A | Stock option (right to buy) | 50,000 | 5.35 | 267.5K | 50,000 | D | ↗ |
| 2026-03-02 | Hunt Jonathan Robert | Officer | A-Award | A | Stock option (right to buy) | 90,000 | 5.35 | 481.5K | 90,000 | D | ↗ |
| 2026-03-02 | HENSON HEIDI | Director | A-Award | A | Stock option (right to buy) | 50,000 | 5.35 | 267.5K | 50,000 | D | ↗ |
| 2025-11-13 | Hunt Jonathan Robert | Officer | P-Purchase | A | Common Stock | 11,000 | 2.03 | 22.3K | 59,800 | D | ↗ |
| 2025-11-12 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 9,498 | 2.10 | 19.9K | 9,864 | I | ↗ |
| 2025-09-04 | Sendek Joel | Officer | A-Award | A | Stock option (right to buy) | 600,000 | 3.54 | 2.12M | 600,000 | D | ↗ |
| 2025-09-03 | Martinez Maria E | Director | A-Award | A | Stock option (right to buy) | 75,000 | 3.38 | 253.5K | 75,000 | D | ↗ |
| 2025-03-31 | Woods Lori A | Director | P-Purchase | A | Common Stock | 23,475 | 2.13 | 50.0K | 183,460 | I | ↗ |
| 2025-03-31 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 38,145 | 2.14 | 81.8K | 108,982 | D | ↗ |
| 2025-03-28 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 22,192 | 2.27 | 50.4K | 70,837 | D | ↗ |
| 2025-03-28 | Spoor Johan M. | Director / Officer | P-Purchase | A | Common Stock | 4,650 | 2.21 | 10.3K | 4,650 | I | ↗ |
| 2025-03-28 | Graham Juan | Officer | P-Purchase | A | Common Stock | 33,333 | 2.25 | 74.9K | 35,354 | D | ↗ |
| 2025-03-03 | Woods Lori A | Director | A-Award | A | Stock option (right to buy) | 50,000 | 2.46 | 123.0K | 50,000 | D | ↗ |
| 2025-03-03 | Williamson Robert F III | Director | A-Award | A | Stock option (right to buy) | 50,000 | 2.46 | 123.0K | 50,000 | D | ↗ |
| 2025-03-03 | Spoor Johan M. | Director / Officer | A-Award | A | Stock option (right to buy) | 650,000 | 2.46 | 1.60M | 650,000 | D | ↗ |
| 2025-03-03 | Puhlmann Markus | Officer | A-Award | A | Stock option (right to buy) | 165,000 | 2.46 | 405.9K | 165,000 | D | ↗ |
| 2025-03-03 | Morich Frank | Director | A-Award | A | Stock option (right to buy) | 50,000 | 2.46 | 123.0K | 50,000 | D | ↗ |
| 2025-03-03 | Hunt Jonathan Robert | Officer | A-Award | A | Stock option (right to buy) | 75,000 | 2.46 | 184.5K | 75,000 | D | ↗ |
| 2025-03-03 | HENSON HEIDI | Director | A-Award | A | Stock option (right to buy) | 50,000 | 2.46 | 123.0K | 50,000 | D | ↗ |
| 2025-01-06 | Graham Juan | Officer | — | — | Common Stock | 0 | 0.00 | — | 2,021 | D | ↗ |
| 2024-12-04 | Spoor Johan M. | Director / Officer | P-Purchase | A | Common Stock | 8,000 | 3.77 | 30.1K | 36,257 | D | ↗ |
| 2024-12-04 | HENSON HEIDI | Director | P-Purchase | A | Common Stock | 25,975 | 3.85 | 100.0K | 25,975 | I | ↗ |
| 2024-11-25 | Williamson Robert F III | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-25 | Spoor Johan M. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-25 | Hunt Jonathan Robert | Officer | P-Purchase | A | Common Stock | 400 | 3.55 | 1.4K | 36,371 | D | ↗ |
| 2024-07-17 | Austin Mark John | Officer | A-Award | A | Stock Option (right to buy) | 34,500 | 11.96 | 412.6K | 34,500 | — | ↗ |
| 2024-06-20 | Woods Lori A | Director | A-Award | A | Stock option (right to buy) | 23,000 | 10.65 | 245.0K | 23,000 | — | ↗ |
| 2024-06-20 | Williamson Robert F III | Director | A-Award | A | Stock option (right to buy) | 23,000 | 10.65 | 245.0K | 23,000 | — | ↗ |
| 2024-06-20 | Spoor Johan M. | Director / Officer | A-Award | A | Stock option (right to buy) | 500,000 | 10.65 | 5.33M | 500,000 | — | ↗ |
| 2024-06-20 | Puhlmann Markus | Officer | A-Award | A | Stock option (right to buy) | 150,000 | 10.65 | 1.60M | 150,000 | — | ↗ |
| 2024-06-20 | Morich Frank | Director | A-Award | A | Stock option (right to buy) | 23,000 | 10.65 | 245.0K | 23,000 | — | ↗ |
| 2024-06-20 | Hunt Jonathan Robert | Officer | A-Award | A | Stock option (right to buy) | 100,000 | 10.65 | 1.07M | 100,000 | — | ↗ |
| 2024-06-20 | HENSON HEIDI | Director | A-Award | A | Stock option (right to buy) | 23,000 | 10.65 | 245.0K | 23,000 | — | ↗ |
| 2024-06-17 | Hunt Jonathan Robert | Officer | P-Purchase | A | Common Stock | 1,800 | 9.82 | 17.7K | 35,971 | — | ↗ |
| 2024-06-14 | Woods Lori A | Director | P-Purchase | A | Common Stock | 83 | 10.80 | 896.40 | 159,985 | — | ↗ |
| 2024-06-13 | Spoor Johan M. | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 1.17 | 117.4K | 137,572 | — | ↗ |
| 2024-06-03 | Woods Lori A | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-31 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 55,000 | 1.38 | 75.9K | 423,792 | — | ↗ |
| 2024-05-31 | Hunt Jonathan Robert | Officer | P-Purchase | A | Common Stock | 12,000 | 1.40 | 16.8K | 341,716 | — | ↗ |
| 2024-05-29 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 11,375 | 1.32 | 15.0K | 350,136 | — | ↗ |
| 2024-04-23 | Austin Mark John | Officer | M-Exempt | D | Stock option (right to buy) | 30,000 | 0.36 | 10.8K | 120,000 | — | ↗ |
| 2024-03-06 | Lantheus Alpha Therapy, LLC | 10% Owner | P-Purchase | A | Common Stock | 60,431,039 | 0.95 | 57.41M | 116,773,394 | — | ↗ |
| 2024-01-30 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 3,500 | 0.70 | 2.5K | 338,761 | — | ↗ |
| 2024-01-29 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 21,235 | 0.64 | 13.6K | 211,555 | — | ↗ |
| 2024-01-26 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 14,850 | 0.61 | 9.1K | 102,776 | — | ↗ |
| 2024-01-25 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 22,134 | 0.49 | 10.8K | 75,676 | — | ↗ |
| 2024-01-24 | Williamson Robert F III | Director | P-Purchase | A | Common Stock | 29,862 | 0.49 | 14.6K | 53,542 | — | ↗ |
| 2024-01-24 | Puhlmann Markus | Officer | P-Purchase | A | Common Stock | 280,000 | 0.50 | 139.9K | 1,375,425 | — | ↗ |
| 2024-01-22 | Lantheus Alpha Therapy, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 56,342,355 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-7.5K
Shares Outstanding
73.67M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Johan (Thijs) Spoor CEO and Director | 680.0K | — | — | 1.30M | 408.0K | 14.0K | 2.40M | 54.17% | ↗ |
| 2 | 2025 | Juan Graham Former Chief Financial Officer | 334.7K | 80.0K | — | 1.16M | — | 660.4K | 2.23M | 51.89% | ↗ |
| 3 | 2025 | Joel Sendek Chief Financial Officer | 163.0K | — | — | 1.75M | 65.2K | 7.5K | 1.99M | 88.13% | ↗ |
| 4 | 2025 | Markus Puhlmann, M.D. Chief Medical Officer | 516.7K | — | — | 330.7K | 206.7K | 14.0K | 1.07M | 30.96% | ↗ |
| 5 | 2024 | Johan (Thijs) Spoor CEO and Director | 630.0K | — | — | 4.42M | 315.0K | 13.8K | 5.38M | 82.19% | ↗ |
| 6 | 2024 | Markus Puhlmann, M.D. Chief Medical Officer | 496.8K | — | — | 1.33M | 198.7K | 13.8K | 2.04M | 65.17% | ↗ |
| 7 | 2024 | Jonathan Hunt Chief Financial Officer | 447.4K | — | — | 884.7K | 150.0K | 13.8K | 1.50M | 59.14% | ↗ |
| 8 | 2023 | Johan (Thijs) Spoor CEO and Director | 506.3K | 21.7K | — | 603.2K | 287.5K | 40.3K | 1.46M | 41.34% | ↗ |
| 9 | 2023 | Jonathan Hunt Chief Financial Officer | 389.2K | 30.0K | — | 225.6K | 172.0K | 353.2K | 1.17M | 19.28% | ↗ |
| 10 | 2023 | Markus Puhlmann, M.D. Chief Medical Officer | 420.8K | 3.3K | — | 267.0K | 184.0K | 25.0K | 900.1K | 29.66% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Johan Spoor | Chief Executive Officer & Director | 1M | male |
| Markus Puhlmann | Chief Medical Officer | 737.4K | — |
| Jonathan R. Hunt | Chief Accounting Officer | 611.2K | male |
| Joel David Sendek | CFO & Principal Financial Officer | 574.3K | male |
| Michael K. Schultz | Chief Science Officer | — | — |
| Amos Hedt PGradDip | Chief Business Strategy Officer | — | male |
| Shane Cobb | Executive Vice President of Operations | — | male |
| Andrew Bright | Executive Vice President of Brachytherapy | — | male |
| Annie J. Cheng | Vice President of Investor Relations | — | female |
| Chris Nenno | General Counsel & Corporate Secretary | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CATX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
